Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of “Buy” from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned an average rating of “Buy” from the ten brokerages that are currently covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $73.38.

JSPR has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. BMO Capital Markets began coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Royal Bank of Canada reissued an “outperform” rating and issued a $68.00 price target on shares of Jasper Therapeutics in a research report on Monday, December 23rd. Finally, HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th.

Jasper Therapeutics Trading Up 2.1 %

Shares of JSPR stock opened at $21.38 on Wednesday. Jasper Therapeutics has a 12 month low of $6.41 and a 12 month high of $31.01. The firm has a market capitalization of $320.72 million, a PE ratio of -4.51 and a beta of 2.18. The firm has a fifty day simple moving average of $22.02 and a two-hundred day simple moving average of $20.56.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently modified their holdings of JSPR. JPMorgan Chase & Co. grew its holdings in Jasper Therapeutics by 239.8% during the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock valued at $308,000 after purchasing an additional 11,567 shares during the period. Barclays PLC increased its holdings in Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after acquiring an additional 12,308 shares during the last quarter. Jane Street Group LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at about $251,000. Wellington Management Group LLP purchased a new stake in Jasper Therapeutics during the third quarter valued at about $447,000. Finally, State Street Corp boosted its position in Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after purchasing an additional 23,564 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.